Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week Low – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $17.50 and last traded at $18.41, with a volume of 421803 shares. The stock had previously closed at $17.91.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. William Blair assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “overweight” rating and a $30.00 target price on the stock. Leerink Partners initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price for the company. Finally, TD Cowen began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics presently has an average rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Performance

The company has a market cap of $2.25 billion and a P/E ratio of -0.00. The firm’s 50-day moving average price is $20.54.

Kailera Therapeutics (NASDAQ:KLRA) last issued its quarterly earnings data on Tuesday, May 26th. The company reported ($3,650.00) EPS for the quarter.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.